Skip to main content

Advertisement

SpringerLink
Log in

Treatment of Unresectable Liver-Only Disease: Systemic Therapy versus Locoregional Therapy

  • COLORECTAL LIVER METASTASES (S WEBER, SECTION EDITOR)
  • Published:
Current Surgery Reports Aims and scope Submit manuscript

Abstract

Most patients with colorectal liver metastases present with unresectable/disseminated disease and are treated with palliative therapies. Patients with unresectable liver only disease represent a large subset that similarly has a poor prognosis. Numerous reports pertaining to local and systemic therapies have been published, there are however few methodologically rigorous studies to define the best approach in these patients. Most information comes from retrospective reports at high volume centers, which does not necessarily represent the current treatment for the majority of patients. The aim of this review is to analyze the current systemic and local treatments utilized in these patients with the aim of defining the ideal approach for them.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Recently published papers of particular interest have been highlighted as: • Of importance •• Of major importance

  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.

    Article  PubMed  Google Scholar 

  2. House MG, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210(5):744–52 752–5.

    Article  PubMed  Google Scholar 

  3. Butte JM, et al. Patterns of failure in patients with early onset (synchronous) resectable liver metastases from rectal cancer. Cancer. 2012;118(21):5414–23.

    Article  PubMed  Google Scholar 

  4. Carpizo DR, et al. Liver resection for metastatic colorectal cancer in patients with concurrent extrahepatic disease: results in 127 patients treated at a single center. Ann Surg Oncol. 2009;16(8):2138–46.

    Article  PubMed  Google Scholar 

  5. Adam R, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644–57 discussion 657-8.

    PubMed Central  PubMed  Google Scholar 

  6. Adam R, et al. Patients with initially unresectable colorectal liver metastases: is there a possibility of cure? J Clin Oncol. 2009;27(11):1829–35.

    Article  PubMed  Google Scholar 

  7. Abdalla EK, et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol. 2006;13(10):1271–80.

    Article  PubMed  Google Scholar 

  8. Adams RB, et al. Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013;15(2):91–103.

    Article  PubMed Central  Google Scholar 

  9. • Cardona K et al. Treatment of extensive metastatic colorectal cancer to the liver with systemic and hepatic arterial infusion chemotherapy and two-stage hepatic resection: the role of salvage therapy for recurrent disease. Ann Surg Oncol 2013. This study analyzed the recurrence pattern, salvage rate, and survival after two-stage hepatectomy combined with systemic and regional chemotherapy.

  10. Hemming AW, et al. Resection of the liver and inferior vena cava for hepatic malignancy. J Am Coll Surg. 2013;217(1):115–24 discussion 124-5.

    Article  PubMed  Google Scholar 

  11. Lodge JP, et al. Ex vivo and in situ resection of inferior vena cava with hepatectomy for colorectal metastases. Ann Surg. 2000;231(4):471–9.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  12. Yamamoto Y. Ante-situm hepatic resection for tumors involving the confluence of hepatic veins and IVC. J Hepatobiliary Pancreat Sci. 2013;20(3):313–23.

    Article  PubMed  Google Scholar 

  13. Malde DJ, et al. Inferior vena cava resection with hepatectomy: challenging but justified. HPB (Oxford). 2011;13(11):802–10.

    Article  Google Scholar 

  14. Mehrabi A, et al. Hypothermic ante situm resection in tumors of the hepatocaval confluence. Dig Surg. 2011;28(2):100–8.

    Article  PubMed  Google Scholar 

  15. Schnitzbauer AA, et al. Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg. 2012;255(3):405–14.

    Article  PubMed  Google Scholar 

  16. Shindoh J, et al. Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol. 2013;20(8):2493–500.

    Article  PubMed  Google Scholar 

  17. Huang SY, et al. Efficacy and safety of portal vein embolization for two-stage hepatectomy in patients with colorectal liver metastasis. J Vasc Interv Radiol. 2013;. doi:10.1016/j.jvir.2013.10.028.

    Google Scholar 

  18. Shindoh J, et al. Safety and efficacy of portal vein embolization before planned major or extended hepatectomy: an institutional experience of 358 patients. J Gastrointest Surg. 2013;. doi:10.1007/s11605-013-2369-0.

    PubMed Central  Google Scholar 

  19. Shindoh J, et al. Portal vein embolization improves rate of resection of extensive colorectal liver metastases without worsening survival. Br J Surg. 2013;100(13):1777–83.

    Article  PubMed  CAS  Google Scholar 

  20. Shindoh J, et al. Analysis of the efficacy of portal vein embolization for patients with extensive liver malignancy and very low future liver remnant volume, including a comparison with the associating liver partition with portal vein ligation for staged hepatectomy approach. J Am Coll Surg. 2013;217(1):126–33 discussion 133-4.

    Article  PubMed  Google Scholar 

  21. Covey AM, et al. Combined portal vein embolization and neoadjuvant chemotherapy as a treatment strategy for resectable hepatic colorectal metastases. Ann Surg. 2008;247(3):451–5.

    Article  PubMed  Google Scholar 

  22. • Fischer C et al. Chemotherapy after portal vein embolization to protect against tumor growth during liver hypertrophy before hepatectomy. JAMA Surg 2013. This study shows the impact of chemotherapy on tumor growth after portal vein embolization.

  23. Reddy SK, et al. Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis. Ann Surg Oncol. 2009;16(7):1809–19.

    Article  PubMed  Google Scholar 

  24. Brouquet A, et al. High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol. 2011;29(8):1083–90.

    Article  PubMed Central  PubMed  Google Scholar 

  25. Bismuth H, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg. 1996;224(4):509–20 discussion 520-2.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  26. Kornprat P, et al. Outcome after hepatectomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol. 2007;14(3):1151–60.

    Article  PubMed  Google Scholar 

  27. • Ardito F et al. Chance of cure following liver resection for initially unresectable colorectal metastases: analysis of actual 5-year survival. J Gastrointest Surg, 2013; 17(2): 352–9. “This study shows the possibility of cure in patients with unresectable disease, treated with chemotherapy and surgery.”

  28. Alberts SR, et al. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol. 2005;23(36):9243–9.

    Article  PubMed  CAS  Google Scholar 

  29. Ychou M, et al. Tritherapy with fluorouracil/leucovorin, irinotecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metastases. Cancer Chemother Pharmacol. 2008;62(2):195–201.

    Article  PubMed  CAS  Google Scholar 

  30. Masi G, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249(3):420–5.

    Article  PubMed  Google Scholar 

  31. Skof E, et al. Capecitabine plus irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial. BMC Cancer. 2009;9:120.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  32. Zhao R, et al. A phase II study of irinotecan and capecitabine for patients with unresectable liver-only metastases from colorectal cancer. Jpn J Clin Oncol. 2010;40(1):10–6.

    Article  PubMed  CAS  Google Scholar 

  33. Wong R, et al. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection. Ann Oncol. 2011;22(9):2042–8.

    Article  PubMed  CAS  Google Scholar 

  34. •• Takahashi T et al. Multicenter phase II study of modified FOLFOX6 as neoadjuvant chemotherapy for patients with unresectable liver-only metastases from colorectal cancer in Japan: ROOF study. Int J Clin Oncol. 2013;18(2): 335–42. This trial shows the role of FOLFOX in patients with unresectable, liver only disease.

  35. •• Ji JH et al. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. Cancer Chemother Pharmacol. 2013; 72(1): 223–30. This trial shows the effect of FOLFOX plus cetuximab in patients with liver only, unresectable disease.

  36. Kemeny N, Fata F. Hepatic-arterial chemotherapy. Lancet Oncol. 2001;2(7):418–28.

    Article  PubMed  CAS  Google Scholar 

  37. Kingham TP, D’Angelica M, Kemeny NE. Role of intra-arterial hepatic chemotherapy in the treatment of colorectal cancer metastases. J Surg Oncol. 2010;102(8):988–95.

    Article  PubMed  Google Scholar 

  38. Kemeny N, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol. 2005;23(22):4888–96.

    Article  PubMed  CAS  Google Scholar 

  39. Kemeny N, et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol. 2001;19(10):2687–95.

    PubMed  CAS  Google Scholar 

  40. Kemeny NE, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol. 2009;27(21):3465–71.

    Article  PubMed Central  PubMed  Google Scholar 

  41. Allen PJ, et al. Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg. 2005;201(1):57–65.

    Article  PubMed  Google Scholar 

  42. Ito K, et al. Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors. Ann Surg Oncol. 2012;19(5):1609–17.

    Article  PubMed  Google Scholar 

  43. Kemeny N, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med. 1999;341(27):2039–48.

    Article  PubMed  CAS  Google Scholar 

  44. Kemeny N, et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol. 2009;20(7):1236–41.

    Article  PubMed  CAS  Google Scholar 

  45. Kemeny NE, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol. 2006;24(9):1395–403.

    Article  PubMed  CAS  Google Scholar 

  46. Kemeny N, et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med. 1987;107(4):459–65.

    Article  CAS  Google Scholar 

  47. •• Ammori JB et al. Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution. Ann Surg Oncol. 2013; 20(9): 2901–7. This study shows the natural history of patients with unresectable liver metastases from colorectal cancer treated initially with hepatic artery infusional chemotherapy.

  48. Abdalla EK, et al. Locoregional surgical and interventional therapies for advanced colorectal cancer liver metastases: expert consensus statements. HPB (Oxford). 2013;15(2):119–30.

    Article  Google Scholar 

  49. Stubbs RS, Cannan RJ, Mitchell AW. Selective internal radiation therapy with 90yttrium microspheres for extensive colorectal liver metastases. J Gastrointest Surg. 2001;5(3):294–302.

    Article  PubMed  CAS  Google Scholar 

  50. Gray BN, et al. Regression of liver metastases following treatment with yttrium-90 microspheres. Aust N Z J Surg. 1992;62(2):105–10.

    Article  PubMed  CAS  Google Scholar 

  51. •• Gray B et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12(12): 1711–20.

  52. Lim L, et al. A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy. BMC Cancer. 2005;5:132.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  53. Cianni R, et al. Selective internal radiation therapy with SIR-spheres for the treatment of unresectable colorectal hepatic metastases. Cardiovasc Intervent Radiol. 2009;32(6):1179–86.

    Article  PubMed  Google Scholar 

  54. Hong K, et al. Salvage therapy for liver-dominant colorectal metastatic adenocarcinoma: comparison between transcatheter arterial chemoembolization versus yttrium-90 radioembolization. J Vasc Interv Radiol. 2009;20(3):360–7.

    Article  PubMed  Google Scholar 

  55. Turkmen C, et al. Initial outcome after selective intraarterial radionuclide therapy with yttrium-90 microspheres as salvage therapy for unresectable metastatic liver disease. Cancer Biother Radiopharm. 2013;28(7):534–40.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service of Hepatobiliary and Pancreatic Surgery, Division of General Surgery, Faculty of Medicine, Foothills Medical Centre, University of Calgary, EG-26, Foothills Medical Centre, 1403-29 Street NW, Calgary, AB, T2N 2T9, Canada

    Jean M. Butte, Chad G. Ball & Elijah Dixon

Authors
  1. Jean M. Butte
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chad G. Ball
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elijah Dixon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elijah Dixon.

Additional information

This article is part of the Topical Collection on Colorectal Liver Metastases.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Butte, J.M., Ball, C.G. & Dixon, E. Treatment of Unresectable Liver-Only Disease: Systemic Therapy versus Locoregional Therapy. Curr Surg Rep 2, 50 (2014). https://doi.org/10.1007/s40137-014-0050-5

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s40137-014-0050-5

Keywords

Search

Navigation